No Detail Found!

The impact of hormone receptor status on survival and recurrence of HER2-positive breast cancers in standard adjuvant setting: A retrospective study in Tehran, Iran

Author(s)
Safa Najafi Department of Breast Diseases, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Masoud Sadeghi Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad Reza Shajari Department of Breast Diseases, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Fatemeh Abasvandi Department of Breast Diseases, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Kamran Mohebi Department of Breast Diseases, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Abstract
Objective: To evaluate hormone receptor status on survival and recurrence of the human epidermal growth factor receptor 2-positive breast cancer treated with Trastuzumab in the adjuvant setting. Methods: The retrospective study was conducted in 2017 at the Breast Cancer Research Centre, Tehran University of Medical Sciences, Tehran, Iran, and comprised data of women aged >20 years with stage I-III of human epidermal growth factor receptor 2-positive breast cancer who were treated with Trastuzumab from 2008 to 2017. The patients were divided into two groups. Group P had patients who were triple positive for human epidermal growth factor receptor 2, oestrogen receptor and progesterone receptor. Group N had patients positive for only human epidermal growth factor receptor 2. All patients in group P were treated with hormone therapy. Overall survival, disease-free survival, and distant metastasis rates were measured. SPSS 22 was used for data analysis. Results: Of the 263 patients, 169(%) were in group P with a mean age of 46.86 ± 10.92 years, and 94(%) were in group N with a mean age of 48.53±12.33 years (p>0.05). There were no unfavourable predictors for overall survival and disease-free survival except for stage (p<0.05). The difference on both counts between the groups was not significant (p>0.05 each). Conclusion: The impact of hormone receptor positivity on survival and progression of human epidermal growth factor receptor 2-positive breast cancer remains an area of debate.
Publication Details
Page(s) 11-16
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 70, Issue: 1, Year: 2020

Request the full text from PASTIC

Keywords
Breast cancer, Survival., Hormone receptor, HER2, Trastuzumab
0

Citations

0

Downloads

87

Views